{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T13:28:38Z","timestamp":1793021318667,"version":"4.5.0"},"reference-count":286,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003345","name":"Chinese Academy of Meteorological Sciences","doi-asserted-by":"publisher","award":["2016-I2M-1-004"],"award-info":[{"award-number":["2016-I2M-1-004"]}],"id":[{"id":"10.13039\/501100003345","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003345","name":"Chinese Academy of Meteorological Sciences","doi-asserted-by":"publisher","award":["81473376"],"award-info":[{"award-number":["81473376"]}],"id":[{"id":"10.13039\/501100003345","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003345","name":"Chinese Academy of Meteorological Sciences","doi-asserted-by":"publisher","award":["81730096"],"award-info":[{"award-number":["81730096"]}],"id":[{"id":"10.13039\/501100003345","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003345","name":"Chinese Academy of Meteorological Sciences","doi-asserted-by":"publisher","award":["81773924"],"award-info":[{"award-number":["81773924"]}],"id":[{"id":"10.13039\/501100003345","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2016-I2M-1-004"],"award-info":[{"award-number":["2016-I2M-1-004"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81473376"],"award-info":[{"award-number":["81473376"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81730096"],"award-info":[{"award-number":["81730096"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773924"],"award-info":[{"award-number":["81773924"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.phrs.2021.105761","type":"journal-article","created":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T03:30:12Z","timestamp":1625628612000},"page":"105761","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"special_numbering":"C","title":["Novel rapid-acting glutamatergic modulators: Targeting the synaptic plasticity in depression"],"prefix":"10.1016","volume":"171","author":[{"given":"Ya-Ting","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Le","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Tong","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nai-Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-Zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7422-8206","authenticated-orcid":false,"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2021.105761_bib1","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1001\/jama.289.23.3095","article-title":"The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)","volume":"289","author":"Kessler","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2021.105761_bib2","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1176\/appi.ajp.2015.15040465","article-title":"Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression","volume":"172","author":"Newport","year":"2015","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.116778","article-title":"Ketamine and nitrous oxide: the evolution of NMDA receptor antagonists as antidepressant agents","volume":"412","author":"Kalmoe","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.phrs.2021.105761_bib4","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STARD report","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.pneurobio.2015.12.001","article-title":"New targets for rapid antidepressant action","volume":"152","author":"Machado-Vieira","year":"2017","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.phrs.2021.105761_bib6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/jamapsychiatry.2016.2586","article-title":"Toward an evidence-based, operational definition of treatment-resistant depression: when enough is enough","volume":"74","author":"Conway","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"Suppl. 16","key":"10.1016\/j.phrs.2021.105761_bib7","first-page":"S10","article-title":"The definition and meaning of treatment-resistant depression","volume":"62","author":"Sackeim","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib8","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1146\/annurev-med-053013-062946","article-title":"Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics","volume":"66","author":"Abdallah","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.phrs.2021.105761_bib9","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/mp.2015.92","article-title":"Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder","volume":"20","author":"Papakostas","year":"2015","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib10","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.neubiorev.2009.01.004","article-title":"Bipolar and major depressive disorder: neuroimaging the developmental-degenerative divide","volume":"33","author":"Savitz","year":"2009","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.phrs.2021.105761_bib11","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1126\/science.1222939","article-title":"Synaptic dysfunction in depression: potential therapeutic targets","volume":"338","author":"Duman","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.phrs.2021.105761_bib12","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.biopsych.2012.11.009","article-title":"The action of antidepressants on the glutamate system: regulation of glutamate release and glutamate receptors","volume":"73","author":"Musazzi","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib13","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nrd2462","article-title":"Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders","volume":"7","author":"Sanacora","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2021.105761_bib14","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.neuropharm.2011.07.036","article-title":"Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders","volume":"62","author":"Sanacora","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2021.105761_bib15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1152\/physrev.1958.38.1.91","article-title":"Post-tetanic potentiation","volume":"38","author":"Hughes","year":"1958","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.phrs.2021.105761_bib16","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.conb.2010.06.010","article-title":"Synaptic stability and plasticity in a floating world","volume":"20","author":"Gerrow","year":"2010","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.phrs.2021.105761_bib17","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/S0166-2236(02)02269-5","article-title":"Long-term plasticity at GABAergic and glycinergic synapses: mechanisms and functional significance","volume":"25","author":"Gaiarsa","year":"2002","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.phrs.2021.105761_bib18","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.tins.2010.01.001","article-title":"Structural dynamics of dendritic spines in memory and cognition","volume":"33","author":"Kasai","year":"2010","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.phrs.2021.105761_bib19","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/sj.npp.1301559","article-title":"Synaptic plasticity: multiple forms, functions, and mechanisms","volume":"33","author":"Citri","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.phrs.2021.105761_bib20","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.pnpbp.2012.12.012","article-title":"Synaptic plasticity in depression: molecular, cellular and functional correlates","volume":"43","author":"Marsden","year":"2013","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib21","doi-asserted-by":"crossref","first-page":"10461","DOI":"10.1523\/JNEUROSCI.2579-06.2006","article-title":"Different mechanisms exist for the plasticity of glutamate reuptake during early long-term potentiation (LTP) and late LTP","volume":"26","author":"Pita-Almenar","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.phrs.2021.105761_bib22","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.mcn.2007.10.015","article-title":"Plasticity-dependent changes in metabotropic glutamate receptor expression at excitatory hippocampal synapses","volume":"37","author":"Cheyne","year":"2008","journal-title":"Mol. Cell Neurosci."},{"key":"10.1016\/j.phrs.2021.105761_bib23","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0028-3908(02)00342-8","article-title":"An increased expression of the mGlu5 receptor protein following LTP induction at the perforant path-dentate gyrus synapse in freely moving rats","volume":"44","author":"Manahan-Vaughan","year":"2003","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2021.105761_bib24","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1126\/scitranslmed.3002804","article-title":"Translating glutamate: from pathophysiology to treatment","volume":"3","author":"Javitt","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.phrs.2021.105761_bib25","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.pnpbp.2015.02.015","article-title":"Role of calcium, glutamate and NMDA in major depression and therapeutic application","volume":"64","author":"Deutschenbaur","year":"2016","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib26","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/340474a0","article-title":"Rapid increase of an immediate early gene messenger RNA in hippocampal neurons by synaptic NMDA receptor activation","volume":"340","author":"Cole","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2021.105761_bib27","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/319774a0","article-title":"Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5","volume":"319","author":"Morris","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2021.105761_bib28","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1177\/0269881108089818","article-title":"The group II metabotropic glutamate receptor 3 (mGluR3, mGlu3, GRM3): expression, function and involvement in schizophrenia","volume":"22","author":"Harrison","year":"2008","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.phrs.2021.105761_bib29","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1126\/science.287.5461.2262","article-title":"Driving AMPA receptors into synapses by LTP and CaMKII: requirement for GluR1 and PDZ domain interaction","volume":"287","author":"Hayashi","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.phrs.2021.105761_bib30","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2165\/11586650-000000000-00000","article-title":"Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia","volume":"25","author":"Singh","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1016\/j.phrs.2021.105761_bib31","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1021\/cn400023y","article-title":"Is there a path forward for mGlu(2) positive allosteric modulators for the treatment of schizophrenia?","volume":"4","author":"Hopkins","year":"2013","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.phrs.2021.105761_bib32","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1517\/13543776.2013.777043","article-title":"mGluR2 positive allosteric modulators: a patent review (2009 \u2013 present)","volume":"23","author":"Trabanco","year":"2013","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.phrs.2021.105761_bib33","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nrd.2017.16","article-title":"Targeting glutamate signalling in depression: progress and prospects","volume":"16","author":"Murrough","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2021.105761_bib34","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3389\/fnmol.2017.00451","article-title":"Astroglial glutamate signaling and uptake in the hippocampus","volume":"10","author":"Rose","year":"2017","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.phrs.2021.105761_bib35","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00702-013-1130-x","article-title":"Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder","volume":"121","author":"Niciu","year":"2014","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.phrs.2021.105761_bib36","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1471-4159.2006.03913.x","article-title":"The glutamate\/GABA-glutamine cycle: aspects of transport, neurotransmitter homeostasis and ammonia transfer","volume":"98","author":"Bak","year":"2006","journal-title":"J. Neurochem."},{"key":"10.1016\/j.phrs.2021.105761_bib37","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1046\/j.1440-1681.2002.03770.x","article-title":"Roles and regulation of glutamate transporters in the central nervous system","volume":"29","author":"O\u2019Shea","year":"2002","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.phrs.2021.105761_bib38","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.bbi.2019.06.015","article-title":"Markers of central inflammation in major depressive disorder: a systematic review and meta-analysis of studies examining cerebrospinal fluid, positron emission tomography and post-mortem brain tissue","volume":"81","author":"Enache","year":"2019","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.phrs.2021.105761_bib39","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3389\/fpsyt.2018.00561","article-title":"Elevated glutamate and glutamine levels in the cerebrospinal fluid of patients with probable Alzheimer\u2019s disease and depression","volume":"9","author":"Madeira","year":"2018","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib40","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/s41380-018-0252-9","article-title":"Glutamatergic neurometabolite levels in major depressive disorder: a systematic review and meta-analysis of proton magnetic resonance spectroscopy studies","volume":"24","author":"Moriguchi","year":"2019","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib41","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.pnpbp.2010.08.025","article-title":"Elucidating biological risk factors in suicide: role of protein kinase A","volume":"35","author":"Dwivedi","year":"2011","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib42","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.biopsych.2004.03.018","article-title":"Altered protein kinase a in brain of learned helpless rats: effects of acute and repeated stress","volume":"56","author":"Dwivedi","year":"2004","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib43","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.biopsych.2006.04.036","article-title":"Alteration in kinase activity but not in protein levels of protein kinase B and glycogen synthase kinase-3beta in ventral prefrontal cortex of depressed suicide victims","volume":"61","author":"Karege","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib44","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1190287","article-title":"mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists","volume":"329","author":"Li","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.phrs.2021.105761_bib45","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1017\/S1461145706007231","article-title":"Cyclic AMP response element-binding protein in post-mortem brain of teenage suicide victims: specific decrease in the prefrontal cortex but not the hippocampus","volume":"10","author":"Pandey","year":"2007","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.phrs.2021.105761_bib46","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.pnpbp.2011.05.010","article-title":"The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder","volume":"35","author":"Jernigan","year":"2011","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib47","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1017\/S1461145712000016","article-title":"Altered expression of synapse and glutamate related genes in post-mortem hippocampus of depressed subjects","volume":"16","author":"Duric","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.phrs.2021.105761_bib48","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.pnpbp.2008.10.005","article-title":"Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression","volume":"33","author":"Feyissa","year":"2009","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib49","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0301-0082(90)90013-7","article-title":"Metabolism and role of glutamate in mammalian brain","volume":"35","author":"Ereci\u0144ska","year":"1990","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.phrs.2021.105761_bib50","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/mp.2010.80","article-title":"The hippocampus in major depression: evidence for the convergence of the bench and bedside in psychiatric research?","volume":"16","author":"MacQueen","year":"2011","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib51","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/npp.2009.104","article-title":"Neurocircuitry of mood disorders","volume":"35","author":"Price","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.phrs.2021.105761_bib52","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.biopsych.2014.06.018","article-title":"Illness progression, recent stress, and morphometry of hippocampal subfields and medial prefrontal cortex in major depression","volume":"77","author":"Treadway","year":"2015","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib53","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1038\/nm.2886","article-title":"Decreased expression of synapse-related genes and loss of synapses in major depressive disorder","volume":"18","author":"Kang","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2021.105761_bib54","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nm.3513","article-title":"REDD1 is essential for stress-induced synaptic loss and depressive behavior","volume":"20","author":"Ota","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2021.105761_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euroneuro.2009.08.003","article-title":"Regulation of adult neurogenesis by stress, sleep disruption, exercise and inflammation: implications for depression and antidepressant action","volume":"20","author":"Lucassen","year":"2010","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.phrs.2021.105761_bib56","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.pnpbp.2006.03.036","article-title":"Correlation between plasma levels of glutamate, alanine and serine with severity of depression","volume":"30","author":"Mitani","year":"2006","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib57","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S0006-3223(99)00284-X","article-title":"Increased cerebrospinal fluid glutamine levels in depressed patients","volume":"47","author":"Levine","year":"2000","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib58","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.biopsych.2007.03.017","article-title":"Increased levels of glutamate in brains from patients with mood disorders","volume":"62","author":"Hashimoto","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib59","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.biopsych.2006.01.024","article-title":"Low cerebrospinal fluid glutamate and glycine in refractory affective disorder","volume":"61","author":"Frye","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/aje\/kwr482","article-title":"Vitamin D supplementation and depression in the women\u2019s health initiative calcium and vitamin D trial","volume":"176","author":"Bertone-Johnson","year":"2012","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.phrs.2021.105761_bib61","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nm.4050","article-title":"Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants","volume":"22","author":"Duman","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2021.105761_bib62","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.biopsych.2010.12.015","article-title":"Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure","volume":"69","author":"Li","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib63","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1073\/pnas.0706679105","article-title":"Stress blunts serotonin- and hypocretin-evoked EPSCs in prefrontal cortex: role of corticosterone-mediated apical dendritic atrophy","volume":"105","author":"Liu","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2021.105761_bib64","doi-asserted-by":"crossref","first-page":"7870","DOI":"10.1523\/JNEUROSCI.1184-06.2006","article-title":"Stress-induced alterations in prefrontal cortical dendritic morphology predict selective impairments in perceptual attentional set-shifting","volume":"26","author":"Liston","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.phrs.2021.105761_bib65","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.neuropharm.2011.07.014","article-title":"Stress and anxiety: structural plasticity and epigenetic regulation as a consequence of stress","volume":"62","author":"McEwen","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2021.105761_bib66","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/npp.2015.266","article-title":"The genetics of stress-related disorders: PTSD, depression, and anxiety disorders","volume":"41","author":"Smoller","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.phrs.2021.105761_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cobeha.2016.09.012","article-title":"Prefrontal cortex GABAergic deficits and circuit dysfunction in the pathophysiology and treatment of chronic stress and depression","volume":"14","author":"Ghosal","year":"2017","journal-title":"Curr. Opin. Behav. Sci."},{"key":"10.1016\/j.phrs.2021.105761_bib68","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.biopsych.2017.05.024","article-title":"Somatostatin-positive gamma-aminobutyric acid interneuron deficits in depression: cortical microcircuit and therapeutic perspectives","volume":"82","author":"Fee","year":"2017","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib69","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/bs.apha.2014.11.003","article-title":"GABAergic control of depression-related brain states","volume":"73","author":"Luscher","year":"2015","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.phrs.2021.105761_bib70","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/mp.2010.120","article-title":"The GABAergic deficit hypothesis of major depressive disorder","volume":"16","author":"Luscher","year":"2011","journal-title":"Mol. Psychiatry"},{"issue":"Suppl. 1","key":"10.1016\/j.phrs.2021.105761_bib71","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1038\/sj.mp.4001021","article-title":"Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments","volume":"7","author":"Krystal","year":"2002","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib72","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.biopsych.2013.03.032","article-title":"From pathophysiology to novel antidepressant drugs: glial contributions to the pathology and treatment of mood disorders","volume":"73","author":"Sanacora","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib73","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.biopsych.2004.08.022","article-title":"Cellular changes in the postmortem hippocampus in major depression","volume":"56","author":"Stockmeier","year":"2004","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib74","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/mp.2008.106","article-title":"Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole","volume":"15","author":"Banasr","year":"2010","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib75","doi-asserted-by":"crossref","first-page":"13290","DOI":"10.1073\/pnas.95.22.13290","article-title":"Glial reduction in the subgenual prefrontal cortex in mood disorders","volume":"95","author":"Ong\u00fcr","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2021.105761_bib76","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.bcp.2009.04.008","article-title":"Targeting glial physiology and glutamate cycling in the treatment of depression","volume":"78","author":"Valentine","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.phrs.2021.105761_bib77","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1523\/JNEUROSCI.2302-14.2015","article-title":"Activity-dependent rapid local RhoA synthesis is required for hippocampal synaptic plasticity","volume":"35","author":"Briz","year":"2015","journal-title":"J. Neurosci."},{"key":"10.1016\/j.phrs.2021.105761_bib78","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.biopsych.2016.05.005","article-title":"Glutamate and gamma-aminobutyric acid systems in the pathophysiology of major depression and antidepressant response to ketamine","volume":"81","author":"Lener","year":"2017","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib79","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3389\/fpsyt.2018.00767","article-title":"Glutamatergic dysfunction and glutamatergic compounds for major psychiatric disorders: evidence from clinical neuroimaging studies","volume":"9","author":"Li","year":"2018","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib80","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2174\/1566524015666150330143008","article-title":"Glutamate signaling in synaptogenesis and NMDA receptors as potential therapeutic targets for psychiatric disorders","volume":"15","author":"Ohgi","year":"2015","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.phrs.2021.105761_bib81","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.biopsych.2010.06.016","article-title":"Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders","volume":"68","author":"Y\u00fcksel","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib82","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jamapsychiatry.2015.0071","article-title":"Large-scale network dysfunction in major depressive disorder: a Meta-analysis of resting-state functional connectivity","volume":"72","author":"Kaiser","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib83","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1523\/JNEUROSCI.5531-08.2009","article-title":"NMDA receptor GluN2B (GluR epsilon 2\/NR2B) subunit is crucial for channel function, postsynaptic macromolecular organization, and actin cytoskeleton at hippocampal CA3 synapses","volume":"29","author":"Akashi","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.phrs.2021.105761_bib84","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1001\/archpsyc.58.6.545","article-title":"Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder","volume":"58","author":"Cotter","year":"2001","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib85","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0006-3223(99)00041-4","article-title":"Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression","volume":"45","author":"Rajkowska","year":"1999","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib86","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1038\/sj.npp.1301312","article-title":"Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders","volume":"32","author":"Beneyto","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.phrs.2021.105761_bib87","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1017\/S1461145708008985","article-title":"Elevated levels of NR2A and PSD-95 in the lateral amygdala in depression","volume":"12","author":"Karolewicz","year":"2009","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.phrs.2021.105761_bib88","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/sj.npp.1300781","article-title":"Elevated levels of the NR2C subunit of the NMDA receptor in the locus coeruleus in depression","volume":"30","author":"Karolewicz","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.phrs.2021.105761_bib89","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1038\/sj.npp.1301604","article-title":"Lamina-specific abnormalities of NMDA receptor-associated postsynaptic protein transcripts in the prefrontal cortex in schizophrenia and bipolar disorder","volume":"33","author":"Beneyto","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.phrs.2021.105761_bib90","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nrn3138","article-title":"The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission","volume":"13","author":"Popoli","year":"2011","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.phrs.2021.105761_bib91","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1038\/emboj.2009.236","article-title":"Neurogranin enhances synaptic strength through its interaction with calmodulin","volume":"28","author":"Zhong","year":"2009","journal-title":"EMBO J."},{"key":"10.1016\/j.phrs.2021.105761_bib92","doi-asserted-by":"crossref","first-page":"13311","DOI":"10.1523\/JNEUROSCI.4258-07.2007","article-title":"Functional compartmentalization of endosomal trafficking for the synaptic delivery of AMPA receptors during long-term potentiation","volume":"27","author":"Brown","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.phrs.2021.105761_bib93","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/cne.20008","article-title":"Characterization of synaptogyrin 3 as a new synaptic vesicle protein","volume":"470","author":"Belizaire","year":"2004","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.phrs.2021.105761_bib94","first-page":"192","article-title":"Distinct roles of neurofilament and tubulin gene expression in axonal growth","volume":"138","author":"Hoffman","year":"1988","journal-title":"Ciba Found. Symp."},{"key":"10.1016\/j.phrs.2021.105761_bib95","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0006-8993(95)00057-W","article-title":"Alterations in the N-methyl-D-aspartate (NMDA) receptor complex in the frontal cortex of suicide victims","volume":"675","author":"Nowak","year":"1995","journal-title":"Brain Res."},{"key":"10.1016\/j.phrs.2021.105761_bib96","first-page":"455","article-title":"Reduced potency of zinc to interact with NMDA receptors in hippocampal tissue of suicide victims","volume":"55","author":"Nowak","year":"2003","journal-title":"Pol. J. Pharmacol."},{"key":"10.1016\/j.phrs.2021.105761_bib97","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1038\/sj.npp.1301372","article-title":"Aberrant extracellular signal-regulated kinase (ERK) 5 signaling in hippocampus of suicide subjects","volume":"32","author":"Dwivedi","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.phrs.2021.105761_bib98","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1038\/nm.2219","article-title":"A negative regulator of MAP kinase causes depressive behavior","volume":"16","author":"Duric","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2021.105761_bib99","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1038\/mp.2011.47","article-title":"Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice","volume":"16","author":"Beurel","year":"2011","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib100","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00702-002-0810-8","article-title":"Reduced phosphorylation of cyclic AMP-responsive element binding protein in the postmortem orbitofrontal cortex of patients with major depressive disorder","volume":"110","author":"Yamada","year":"2003","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.phrs.2021.105761_bib101","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/sj.npp.1301276","article-title":"Stressor-specific regulation of distinct brain-derived neurotrophic factor transcripts and cyclic AMP response element-binding protein expression in the postnatal and adult rat hippocampus","volume":"32","author":"Nair","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.phrs.2021.105761_bib102","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00004583-200403000-00017","article-title":"Reduced anterior cingulate cortex glutamatergic concentrations in childhood major depression","volume":"43","author":"Mirza","year":"2004","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib103","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nrn2911","article-title":"Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders","volume":"11","author":"Hardingham","year":"2010","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.phrs.2021.105761_bib104","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2013.0601","article-title":"Organization, control and function of extrasynaptic NMDA receptors","volume":"369","author":"Papouin","year":"2014","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.phrs.2021.105761_bib105","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.neuron.2014.03.030","article-title":"Extrasynaptic NMDA receptor involvement in central nervous system disorders","volume":"82","author":"Parsons","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.phrs.2021.105761_bib106","doi-asserted-by":"crossref","first-page":"9854","DOI":"10.1073\/pnas.0903546106","article-title":"Coupling diverse routes of calcium entry to mitochondrial dysfunction and glutamate excitotoxicity","volume":"106","author":"Stanika","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2021.105761_bib107","doi-asserted-by":"crossref","first-page":"8688","DOI":"10.1523\/JNEUROSCI.6078-08.2009","article-title":"Positive AMPA receptor modulation rapidly stimulates BDNF release and increases dendritic mRNA translation","volume":"29","author":"Jourdi","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.phrs.2021.105761_bib108","doi-asserted-by":"crossref","first-page":"10350","DOI":"10.1523\/JNEUROSCI.0692-07.2007","article-title":"Postsynaptic secretion of BDNF and NT-3 from hippocampal neurons depends on calcium calmodulin kinase II signaling and proceeds via delayed fusion pore opening","volume":"27","author":"Kolarow","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.phrs.2021.105761_bib109","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1471-4159.2004.02734.x","article-title":"NMDA receptor activation results in PKA- and ERK-dependent Mnk1 activation and increased eIF4E phosphorylation in hippocampal area CA1","volume":"91","author":"Banko","year":"2004","journal-title":"J. Neurochem."},{"key":"10.1016\/j.phrs.2021.105761_bib110","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1111\/j.1476-5381.2011.01328.x","article-title":"Signalling pathways underlying structural plasticity of dendritic spines","volume":"163","author":"Patterson","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2021.105761_bib111","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1034\/j.1399-5618.2002.01203.x","article-title":"Antidepressants and neuroplasticity","volume":"4","author":"D\u2019Sa","year":"2002","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.phrs.2021.105761_bib112","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3389\/fnmol.2012.00013","article-title":"A pivotal role of GSK-3 in synaptic plasticity","volume":"5","author":"Bradley","year":"2012","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.phrs.2021.105761_bib113","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1098\/rstb.2006.1894","article-title":"Neurotrophin-regulated signalling pathways","volume":"361","author":"Reichardt","year":"2006","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.phrs.2021.105761_bib114","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1586\/ern.10.176","article-title":"Role of the mTOR signaling pathway in the rapid antidepressant action of ketamine","volume":"11","author":"Hashimoto","year":"2011","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.phrs.2021.105761_bib115","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ceb.2005.09.009","article-title":"Growing roles for the mTOR pathway","volume":"17","author":"Sarbassov","year":"2005","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.phrs.2021.105761_bib116","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.tins.2012.12.010","article-title":"Neuronal plasticity and antidepressant actions","volume":"36","author":"Castr\u00e9n","year":"2013","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.phrs.2021.105761_bib117","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1176\/appi.ajp.2009.10030434","article-title":"Linking molecules to mood: new insight into the biology of depression","volume":"167","author":"Krishnan","year":"2010","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib118","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.4088\/JCP.08m04659","article-title":"Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist","volume":"70","author":"Machado-Vieira","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib119","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1017\/S0033291716000064","article-title":"Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories","volume":"46","author":"Kishimoto","year":"2016","journal-title":"Psychol. Med."},{"key":"10.1016\/j.phrs.2021.105761_bib120","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/mp.2017.190","article-title":"The effects of ketamine on dopaminergic function: meta-analysis and review of the implications for neuropsychiatric disorders","volume":"23","author":"Kokkinou","year":"2018","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib121","unstructured":"Ketamine|Completed Studies|Depression. \u3008https:\/\/clinicaltrials.gov\/ct2\/results?cond=Depression&term=ketamine+&cntry=&state=&city=&dist=\u3009."},{"key":"10.1016\/j.phrs.2021.105761_bib122","unstructured":"Ketamine for Severe Adolescent Depression: Intermediate-Term Safety and Efficacy. \u3008https:\/\/ClinicalTrials.gov\/show\/NCT03889756\u3009."},{"key":"10.1016\/j.phrs.2021.105761_bib123","unstructured":"Study of Ketamine for Depression in Cancer Patients Receiving Palliative Care. \u3008https:\/\/ClinicalTrials.gov\/show\/NCT03410446\u3009."},{"key":"10.1016\/j.phrs.2021.105761_bib124","unstructured":"NRX101 Glx Biomarker Validation Study. \u3008https:\/\/ClinicalTrials.gov\/show\/NCT03402152\u3009."},{"key":"10.1016\/j.phrs.2021.105761_bib125","unstructured":"The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression. \u3008https:\/\/ClinicalTrials.gov\/show\/NCT03156504\u3009."},{"key":"10.1016\/j.phrs.2021.105761_bib126","unstructured":"Open Label Ketamine Treatment for Major Depressive Disorder in Veterans. \u3008https:\/\/ClinicalTrials.gov\/show\/NCT03053830\u3009."},{"key":"10.1016\/j.phrs.2021.105761_bib127","unstructured":"Ketamine for Treatment Resistant Late-Life Depression. \u3008https:\/\/ClinicalTrials.gov\/show\/NCT02556606\u3009."},{"key":"10.1016\/j.phrs.2021.105761_bib128","unstructured":"miRNAs, Suicide, and Ketamine \u2013 Plasma Exosomal microRNAs as Novel Biomarkers for Suicidality and Treatment Outcome. \u3008https:\/\/ClinicalTrials.gov\/show\/NCT02418195\u3009."},{"key":"10.1016\/j.phrs.2021.105761_bib129","unstructured":"Examining The Effect of Ketamine on Glutamate\/Glutamine Cycling. \u3008https:\/\/ClinicalTrials.gov\/show\/NCT02037035\u3009."},{"key":"10.1016\/j.phrs.2021.105761_bib130","unstructured":"The Effects of Ketamine on Respiratory Stimulation and Transpulmonary Pressures. \u3008https:\/\/ClinicalTrials.gov\/show\/NCT01969227\u3009."},{"key":"10.1016\/j.phrs.2021.105761_bib131","unstructured":"Treatment Resistant Depression (Pilot). \u3008https:\/\/ClinicalTrials.gov\/show\/NCT01179009\u3009."},{"key":"10.1016\/j.phrs.2021.105761_bib132","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1038\/npp.2017.94","article-title":"Dose-related effects of adjunctive ketamine in taiwanese patients with treatment-resistant depression","volume":"42","author":"Su","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.phrs.2021.105761_bib133","doi-asserted-by":"crossref","first-page":"e852","DOI":"10.4088\/JCP.17f11738","article-title":"Ketamine for depression, 4: in what dose, at what rate, by what route, for how long, and at what frequency?","volume":"78","author":"Andrade","year":"2017","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib134","doi-asserted-by":"crossref","first-page":"pyv124","DOI":"10.1093\/ijnp\/pyv124","article-title":"Effects of low-dose and very low-dose ketamine among patients with major depression: a systematic review and meta-analysis","volume":"19","author":"Xu","year":"2016","journal-title":"IJNPPY"},{"key":"10.1016\/j.phrs.2021.105761_bib135","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1017\/S1461145711000629","article-title":"A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department","volume":"14","author":"Larkin","year":"2011","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.phrs.2021.105761_bib136","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib137","unstructured":"Ketamine|Interventional Studies|Depression. \u3008https:\/\/clinicaltrials.gov\/ct2\/results?term=ketamine&cond=Depression&age_v=&gndr=&type=Intr&rslt=&Search=Apply\u3009."},{"key":"10.1016\/j.phrs.2021.105761_bib138","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/ijnp\/pyz041","article-title":"(R)-Ketamine induces a greater increase in prefrontal 5-HT release than (S)-ketamine and ketamine metabolites via an AMPA receptor-independent mechanism","volume":"22","author":"Ago","year":"2019","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.phrs.2021.105761_bib139","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00406-020-01110-5","article-title":"Intravenous arketamine for treatment-resistant depression: open-label pilot study","volume":"271","author":"Leal","year":"2021","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.phrs.2021.105761_bib140","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.pbb.2018.07.003","article-title":"Expression of heat shock protein HSP-70 in the retrosplenial cortex of rat brain after administration of (R,S)-ketamine and (S)-ketamine, but not (R)-ketamine","volume":"172","author":"Tian","year":"2018","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.phrs.2021.105761_bib141","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.biopsych.2016.12.020","article-title":"(R)-Ketamine shows greater potency and longer lasting antidepressant effects than its metabolite (2R,6R)-hydroxynorketamine","volume":"82","author":"Yang","year":"2017","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib142","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1038\/s41398-017-0031-4","article-title":"Possible role of the gut microbiota-brain axis in the antidepressant effects of (R)-ketamine in a social defeat stress model","volume":"7","author":"Yang","year":"2017","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib143","unstructured":"Competed (S)-Ketamine Trials. \u3008https:\/\/clinicaltrials.gov\/ct2\/results?term=%28S%29-Ketamine&cond=depression&Search=Apply&recrs=e&age_v=&gndr=&type=&rslt=\u3009."},{"key":"10.1016\/j.phrs.2021.105761_bib144","unstructured":"Active (S)-Ketamine Trials. \u3008https:\/\/clinicaltrials.gov\/ct2\/results?pg=1&load=cart&id=NCT04414943+OR+NCT03927378+OR+NCT04399070+OR+NCT04657107+OR+NCT04876066+OR+NCT04587778+OR+NCT04032301+OR+NCT04227704+OR+NCT04669665+OR+NCT04834427+OR+NCT03065335+OR+NCT04850937+OR+NCT02543983+OR+NCT04939649+OR+NCT04837170+OR+NCT04847245+OR+NCT04480918+OR+NCT02734602+OR+NCT04701866+OR+NCT04159012+OR+NCT04037085+OR+NCT04476446+OR+NCT04425473\u3009."},{"key":"10.1016\/j.phrs.2021.105761_bib145","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1176\/appi.ajp.2018.17060720","article-title":"Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study","volume":"175","author":"Canuso","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib146","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.biopsych.2015.10.018","article-title":"Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study","volume":"80","author":"Singh","year":"2016","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib147","first-page":"1","article-title":"Are we repeating mistakes of the past? A review of the evidence for esketamine","author":"Horowitz","year":"2020","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib148","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S2215-0366(19)30394-3","article-title":"Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval","volume":"6","author":"Turner","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib149","unstructured":"Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine. \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04711005\u3009."},{"key":"10.1016\/j.phrs.2021.105761_bib150","unstructured":"Three Dosing Regimens of Dextromethorphan (DXM) Reportedly Used in Major Depressive Disorder. \u3008https:\/\/ClinicalTrials.gov\/show\/NCT04226352\u3009."},{"key":"10.1016\/j.phrs.2021.105761_bib151","unstructured":"Safety and Efficacy Evaluation of S (+) \u2013 Ketamine in Adults. \u3008https:\/\/ClinicalTrials.gov\/show\/NCT04837170\u3009."},{"key":"10.1016\/j.phrs.2021.105761_bib152","unstructured":"Safety and Efficacy Evaluation of S (+) \u2013 Ketamine in Children. \u3008https:\/\/ClinicalTrials.gov\/show\/NCT04834427\u3009."},{"key":"10.1016\/j.phrs.2021.105761_bib153","unstructured":"Open-Label Safety Study of AXS-05 in Subjects With TRD. \u3008https:\/\/ClinicalTrials.gov\/show\/NCT04634669\u3009."},{"key":"10.1016\/j.phrs.2021.105761_bib154","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jad.2012.01.024","article-title":"The DRD2\/ANKK1 gene is associated with response to add-on dextromethorphan treatment in bipolar disorder","volume":"138","author":"Lee","year":"2012","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.phrs.2021.105761_bib155","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.mehy.2011.02.003","article-title":"Dextromethorphan as a potential rapid-acting antidepressant","volume":"76","author":"Lauterbach","year":"2011","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.phrs.2021.105761_bib156","unstructured":"Open-Label Safety Study of AXS-05 in Subjects With TRD. \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04634669\u3009."},{"key":"10.1016\/j.phrs.2021.105761_bib157","unstructured":"Mechanistic Evaluation of Response in TRD (MERIT) (MERIT). \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04608396\u3009."},{"key":"10.1016\/j.phrs.2021.105761_bib158","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jad.2017.04.072","article-title":"Dextromethorphan\/quinidine pharmacotherapy in patients with treatment resistant depression: a proof of concept clinical trial","volume":"218","author":"Murrough","year":"2017","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.phrs.2021.105761_bib159","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jad.2014.05.050","article-title":"The utility of the combination of dextromethorphan and quinidine in the treatment of bipolar II and bipolar NOS","volume":"167","author":"Kelly","year":"2014","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.phrs.2021.105761_bib160","article-title":"Dextromethorphan and quinidine combination in emotional lability associated with depression: a case report","volume":"14","author":"Messias","year":"2012","journal-title":"Prim. Care Companion CNS Disord."},{"key":"10.1016\/j.phrs.2021.105761_bib161","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/mp.2013.130","article-title":"Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects","volume":"19","author":"Sanacora","year":"2014","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib162","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.biopsych.2012.10.019","article-title":"A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression","volume":"74","author":"Zarate","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib163","unstructured":"Brain Reactivity to Nitrous Oxyde in Depression: An MRI and Ultrasound Study (PROTOBRAIN Pilote). \u3008https:\/\/ClinicalTrials.gov\/show\/NCT04199143\u3009."},{"key":"10.1016\/j.phrs.2021.105761_bib164","unstructured":"Nitrous Oxide for the Treatment of Major Depressive Disorder. \u3008https:\/\/ClinicalTrials.gov\/show\/NCT03869736\u3009."},{"key":"10.1016\/j.phrs.2021.105761_bib165","unstructured":"Nitrous Oxide-Suicidal Ideation. \u3008https:\/\/ClinicalTrials.gov\/show\/NCT03736538\u3009."},{"key":"10.1016\/j.phrs.2021.105761_bib166","unstructured":"CODEPAD (Collaborative Outcomes of DEpression and Pain Associated With Delivery). \u3008https:\/\/ClinicalTrials.gov\/show\/NCT03167905\u3009."},{"key":"10.1016\/j.phrs.2021.105761_bib167","unstructured":"NMDA Receptor Antagonist Nitrous Oxide Targets Affective Brain Circuits. \u3008https:\/\/ClinicalTrials.gov\/show\/NCT02994433\u3009."},{"key":"10.1016\/j.phrs.2021.105761_bib168","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.116778","article-title":"Ketamine and nitrous oxide: the evolution of NMDA receptor antagonists as antidepressant agents","volume":"412","author":"Kalmoe","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.phrs.2021.105761_bib169","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/JCP.0b013e31818a6cea","article-title":"An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder","volume":"28","author":"Preskorn","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2021.105761_bib170","doi-asserted-by":"crossref","first-page":"00198","DOI":"10.1002\/prp2.198","article-title":"Preclinical pharmacology and pharmacokinetics of CERC-301, a GluN2B-selective N-methyl-D-aspartate receptor antagonist","volume":"3","author":"Garner","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.phrs.2021.105761_bib171","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/JCP.0b013e31825d70d6","article-title":"A randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder","volume":"32","author":"Ibrahim","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2021.105761_bib172","unstructured":"B.F.H. Paterson, C. Wang, R. Marcus, A randomized, double-blind, placebo-controlled, sequential parallel study of CERC-301 in the adjunctive treatment of subjects with severe depression and recent active suicidal ideation despite antidepressant treatment, in: Proceedings of the National Network of Depression Centers Annual Conference, 5\u20136\u00a0November 2015, Ann Arbor, Michigan, 2020. \u3008http:\/\/c.eqcdn.com\/_2a1b537df6a6e1398b6806c9b30635ad\/cerecor\/db\/322\/603\/file\/Poster+-+Study+Clin301-201_FINAL.pdf\u3009."},{"key":"10.1016\/j.phrs.2021.105761_bib173","unstructured":"Adjunctive D-Cycloserine in Major Depressive Disorder. \u3008https:\/\/ClinicalTrials.gov\/show\/NCT03937596\u3009."},{"key":"10.1016\/j.phrs.2021.105761_bib174","unstructured":"Cycloserine rTMS Plasticity Augmentation in Depression. \u3008https:\/\/ClinicalTrials.gov\/show\/NCT03511599\u3009."},{"key":"10.1016\/j.phrs.2021.105761_bib175","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1017\/S1461145712000910","article-title":"A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression","volume":"16","author":"Heresco-Levy","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.phrs.2021.105761_bib176","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1128\/AAC.00558-10","article-title":"Structure of the mycobacterium tuberculosis D-alanine:D-alanine ligase, a target of the antituberculosis drug D-cycloserine","volume":"55","author":"Bruning","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.phrs.2021.105761_bib177","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.neuroscience.2015.09.004","article-title":"The long-lasting antidepressant effects of rapastinel (GLYX-13) are associated with a metaplasticity process in the medial prefrontal cortex and hippocampus","volume":"308","author":"Burgdorf","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.phrs.2021.105761_bib178","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1517\/13543784.2014.852536","article-title":"GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists","volume":"23","author":"Moskal","year":"2014","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.phrs.2021.105761_bib179","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/npp.2012.246","article-title":"GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects","volume":"38","author":"Burgdorf","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.phrs.2021.105761_bib180","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.biopsych.2013.02.020","article-title":"Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression","volume":"74","author":"Huang","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib181","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/FBP.0000000000000266","article-title":"Investigation of antidepressant-like and anxiolytic-like actions and cognitive and motor side effects of four N-methyl-D-aspartate receptor antagonists in mice","volume":"28","author":"Refsgaard","year":"2017","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.phrs.2021.105761_bib182","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1503\/jpn.120228","article-title":"Glycine site N-methyl-D-aspartate receptor antagonist 7-CTKA produces rapid antidepressant-like effects in male rats","volume":"38","author":"Zhu","year":"2013","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.phrs.2021.105761_bib183","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/ijnp\/pyaa025","article-title":"A randomized trial of the N-methyl-d-aspartate receptor glycine site antagonist prodrug 4-chlorokynurenine in treatment-resistant depression","volume":"23","author":"Park","year":"2020","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.phrs.2021.105761_bib184","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2174\/1570159X14666160321123221","article-title":"Therapeutic modulation of glutamate receptors in major depressive disorder","volume":"15","author":"Jaso","year":"2017","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.phrs.2021.105761_bib185","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1001\/jamapsychiatry.2016.0838","article-title":"Efficacy and safety of basimglurant as adjunctive therapy for major depression: a randomized clinical trial","volume":"73","author":"Quiroz","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib186","unstructured":"A Study to Investigate JNJ-40411813 in Combination With Levetiracetam in Epilepsy. \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04836559\u3009."},{"key":"10.1016\/j.phrs.2021.105761_bib187","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/tp.2014.124","article-title":"Hippocampal structural and functional changes associated with electroconvulsive therapy response","volume":"4","author":"Abbott","year":"2014","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib188","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.pharma.2015.09.001","article-title":"Psychopharmacology of anxiety and depression: historical aspects, current treatments and perspectives","volume":"74","author":"Javelot","year":"2016","journal-title":"Ann. Pharm. Fr."},{"key":"10.1016\/j.phrs.2021.105761_bib189","unstructured":"Antidepressant Effects of TS-161 in Treatment-Resistant Depression. \u3008https:\/\/ClinicalTrials.gov\/show\/NCT04821271\u3009."},{"key":"10.1016\/j.phrs.2021.105761_bib190","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.neuropharm.2003.10.009","article-title":"MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity","volume":"46","author":"Chaki","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2021.105761_bib191","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.drudis.2018.11.007","article-title":"A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate\/GABA neurotransmitter systems","volume":"24","author":"Wilkinson","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.phrs.2021.105761_bib192","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s40263-021-00816-x","article-title":"Novel glutamatergic modulators for the treatment of mood disorders: current status","volume":"35","author":"Henter","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.phrs.2021.105761_bib193","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.biopsych.2013.03.026","article-title":"Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond","volume":"73","author":"Krystal","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib194","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.neulet.2013.04.045","article-title":"Does increasing the ratio of AMPA-to-NMDA receptor mediated neurotransmission engender antidepressant action? Studies in the mouse forced swim and tail suspension tests","volume":"546","author":"Andreasen","year":"2013","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.phrs.2021.105761_bib195","first-page":"301","article-title":"Interplay between brain BDNF and glutamatergic systems: a brief state of the evidence and association with the pathogenesis of depression","volume":"82","author":"Gulyaeva","year":"2017","journal-title":"Biochemistry"},{"key":"10.1016\/j.phrs.2021.105761_bib196","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/nyas.12223","article-title":"New paradigms for treatment-resistant depression","volume":"1292","author":"Zarate","year":"2013","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.phrs.2021.105761_bib197","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/mp.2017.255","article-title":"Mechanisms of ketamine action as an antidepressant","volume":"23","author":"Zanos","year":"2018","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib198","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature17998","article-title":"NMDAR inhibition-independent antidepressant actions of ketamine metabolites","volume":"533","author":"Zanos","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2021.105761_bib199","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40263-018-0492-x","article-title":"Convergent mechanisms underlying rapid antidepressant action","volume":"32","author":"Zanos","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.phrs.2021.105761_bib200","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1080\/14737175.2019.1643237","article-title":"An update on NMDA antagonists in depression","volume":"19","author":"Pochwat","year":"2019","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.phrs.2021.105761_bib201","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.neuint.2012.01.004","article-title":"Pharmacological modulation of NMDA receptor activity and the advent of negative and positive allosteric modulators","volume":"61","author":"Monaghan","year":"2012","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.phrs.2021.105761_bib202","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0014-2999(94)90516-9","article-title":"Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression","volume":"263","author":"Papp","year":"1994","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2021.105761_bib203","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0014-2999(90)90204-J","article-title":"Functional antagonists at the NMDA receptor complex exhibit antidepressant actions","volume":"185","author":"Trullas","year":"1990","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2021.105761_bib204","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1007\/s12630-018-1088-0","article-title":"Ketamine-based anesthesia improves electroconvulsive therapy outcomes: a randomized-controlled study","volume":"65","author":"Gamble","year":"2018","journal-title":"Can. J. Anaesth."},{"key":"10.1016\/j.phrs.2021.105761_bib205","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S2215-0366(17)30077-9","article-title":"Ketamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression (Ketamine-ECT): a multicentre, double-blind, randomised, parallel-group, superiority trial","volume":"4","author":"Anderson","year":"2017","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib206","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jad.2012.04.032","article-title":"Neuropsychological and mood effects of ketamine in electroconvulsive therapy: a randomised controlled trial","volume":"142","author":"Loo","year":"2012","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.phrs.2021.105761_bib207","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","article-title":"Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses","volume":"51","author":"Krystal","year":"1994","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib208","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.biopsych.2009.04.029","article-title":"Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression","volume":"66","author":"Price","year":"2009","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib209","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib210","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.pnpbp.2011.03.019","article-title":"Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression","volume":"35","author":"Ibrahim","year":"2011","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib211","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/da.22253","article-title":"Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression","volume":"31","author":"Price","year":"2014","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.phrs.2021.105761_bib212","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1017\/S0033291715001506","article-title":"Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial","volume":"45","author":"Murrough","year":"2015","journal-title":"Psychol. Med."},{"key":"10.1016\/j.phrs.2021.105761_bib213","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4088\/JCP.09m05327blu","article-title":"Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder","volume":"71","author":"DiazGranados","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib214","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2016.05.076","article-title":"Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: a double-blind, randomized, controlled trial","volume":"204","author":"Jafarinia","year":"2016","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.phrs.2021.105761_bib215","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s40262-016-0383-6","article-title":"Ketamine: a review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy","volume":"55","author":"Peltoniemi","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.phrs.2021.105761_bib216","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.biopsych.2012.05.003","article-title":"Ketamine for depression: where do we go from here?","volume":"72","author":"Aan Het Rot","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib217","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.biopsych.2012.06.022","article-title":"Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression","volume":"74","author":"Murrough","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib218","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/00000542-200202000-00022","article-title":"Cognitive impairment after small-dose ketamine isomers in comparison to equianalgesic racemic ketamine in human volunteers","volume":"96","author":"Pfenninger","year":"2002","journal-title":"Anesthesiology"},{"key":"10.1016\/j.phrs.2021.105761_bib219","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/jamapsychiatry.2017.0080","article-title":"A consensus statement on the use of ketamine in the treatment of mood disorders","volume":"74","author":"Sanacora","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib220","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/npp.2017.194","article-title":"Ketamine for social anxiety disorder: a randomized, placebo-controlled crossover trial","volume":"43","author":"Taylor","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.phrs.2021.105761_bib221","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/2045125313507739","article-title":"Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy","volume":"4","author":"Caddy","year":"2014","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.phrs.2021.105761_bib222","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1017\/S0033291714001603","article-title":"A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes","volume":"45","author":"McGirr","year":"2015","journal-title":"Psychol. Med."},{"key":"10.1016\/j.phrs.2021.105761_bib223","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/bs.apha.2019.03.002","article-title":"Rapid-acting antidepressants","volume":"86","author":"Witkin","year":"2019","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.phrs.2021.105761_bib224","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.brainresbull.2016.05.016","article-title":"Ketamine abuse potential and use disorder","volume":"126","author":"Liu","year":"2016","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.phrs.2021.105761_bib225","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.drugalcdep.2008.01.024","article-title":"Journey through the K-hole: phenomenological aspects of ketamine use","volume":"95","author":"Muetzelfeldt","year":"2008","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.phrs.2021.105761_bib226","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3109\/15622975.2016.1139747","article-title":"Strategies to mitigate dissociative and psychotomimetic effects of ketamine in the treatment of major depressive episodes: a narrative review","volume":"18","author":"Cooper","year":"2017","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib227","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/14737175.2019.1554434","article-title":"An update on ketamine and its two enantiomers as rapid-acting antidepressants","volume":"19","author":"Zhang","year":"2019","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.phrs.2021.105761_bib228","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41398-019-0624-1","article-title":"Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites","volume":"9","author":"Yang","year":"2019","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib229","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/ALN.0b013e3181ed09a2","article-title":"Taming the ketamine tiger. 1965","volume":"113","author":"Domino","year":"2010","journal-title":"Anesthesiology"},{"key":"10.1016\/j.phrs.2021.105761_bib230","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0022-3565(25)11430-4","article-title":"Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors","volume":"260","author":"Oye","year":"1992","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2021.105761_bib231","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00406-016-0692-7","article-title":"Reduction of dopamine D(2\/3) receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: a PET study in conscious monkeys","volume":"267","author":"Hashimoto","year":"2017","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.phrs.2021.105761_bib232","unstructured":"A Study of HR071603 (Ketamine Nasal Spray) in Healthy Subjects. \u3008https:\/\/ClinicalTrials.gov\/show\/NCT04108234\u3009."},{"key":"10.1016\/j.phrs.2021.105761_bib233","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/jamapsychiatry.2017.3739","article-title":"Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial","volume":"75","author":"Daly","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib234","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.psychres.2015.10.032","article-title":"Meta-analysis of short- and mid-term efficacy of ketamine in unipolar and bipolar depression","volume":"230","author":"Romeo","year":"2015","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.phrs.2021.105761_bib235","unstructured":"Esketamine and Perioperative Depressive Symptoms. \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04425473\u3009."},{"key":"10.1016\/j.phrs.2021.105761_bib236","unstructured":"Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-Resistant Bipolar Depression. \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03965871\u3009."},{"key":"10.1016\/j.phrs.2021.105761_bib237","unstructured":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide. \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03185819\u3009."},{"key":"10.1016\/j.phrs.2021.105761_bib238","unstructured":"A Long-Term Safety Study of Esketamine Nasal Spray in Treatment-Resistant Depression (SUSTAIN-3)."},{"key":"10.1016\/j.phrs.2021.105761_bib239","unstructured":"A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-Resistant Depression. \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03434041\u3009."},{"key":"10.1016\/j.phrs.2021.105761_bib240","unstructured":"A Long-Term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor\/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder (ESCAPE-TRD). \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04338321\u3009."},{"key":"10.1016\/j.phrs.2021.105761_bib241","unstructured":"An Expanded Access Protocol for Esketamine Treatment in Participants with Treatment Resistant Depression (TRD) Who Do Not Have Other Treatment Alternatives. \u3008https:\/\/ClinicalTrials.gov\/show\/NCT04226352\u3009."},{"key":"10.1016\/j.phrs.2021.105761_bib242","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.biopsych.2012.03.004","article-title":"Relationship of ketamine\u2019s plasma metabolites with response, diagnosis, and side effects in major depression","volume":"72","author":"Zarate","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib243","doi-asserted-by":"crossref","first-page":"6441","DOI":"10.1073\/pnas.1819540116","article-title":"(2R,6R)-hydroxynorketamine exerts mGlu(2) receptor-dependent antidepressant actions","volume":"116","author":"Zanos","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2021.105761_bib244","doi-asserted-by":"crossref","first-page":"5160","DOI":"10.1073\/pnas.1816071116","article-title":"Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorketamine do not block NMDA receptor function","volume":"116","author":"Lumsden","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2021.105761_bib245","unstructured":"The Role of HNKs in the Antidepressant Effect of Ketamine. \u3008https:\/\/ClinicalTrials.gov\/show\/NCT03977675\u3009."},{"key":"10.1016\/j.phrs.2021.105761_bib246","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbr.2015.03.024","article-title":"Involvement of AMPA receptors in the antidepressant-like effects of dextromethorphan in mice","volume":"295","author":"Nguyen","year":"2015","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.phrs.2021.105761_bib247","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.neubiorev.2015.03.005","article-title":"The role of \u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors in depression: central mediators of pathophysiology and antidepressant activity?","volume":"52","author":"Freudenberg","year":"2015","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.phrs.2021.105761_bib248","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3109\/10673229.2010.511059","article-title":"Glutamatergic modulators: the future of treating mood disorders?","volume":"18","author":"Zarate","year":"2010","journal-title":"Harv. Rev. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib249","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.euroneuro.2011.08.002","article-title":"Evaluation of sigma (\u03c3) receptors in the antidepressant-like effects of ketamine in vitro and in vivo","volume":"22","author":"Robson","year":"2012","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.phrs.2021.105761_bib250","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.expneurol.2007.06.013","article-title":"A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder","volume":"207","author":"Werling","year":"2007","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.phrs.2021.105761_bib251","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/(SICI)1522-7146(1996)11:5<217::AID-JBT2>3.0.CO;2-N","article-title":"Characterization of [3H]MK-801 binding to N-methyl-D-aspartate receptors in cultured rat cerebellar granule neurons and involvement in glutamate-mediated toxicity","volume":"11","author":"Berman","year":"1996","journal-title":"J. Biochem. Toxicol."},{"key":"10.1016\/j.phrs.2021.105761_bib252","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.mehy.2012.02.012","article-title":"An extension of hypotheses regarding rapid-acting, treatment-refractory, and conventional antidepressant activity of dextromethorphan and dextrorphan","volume":"78","author":"Lauterbach","year":"2012","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.phrs.2021.105761_bib253","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20092288","article-title":"The serotonin syndrome: from molecular mechanisms to clinical practice","volume":"20","author":"Francescangeli","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2021.105761_bib254","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/13543784.2017.1267726","article-title":"AVP-786 for the treatment of agitation in dementia of the Alzheimer\u2019s type","volume":"26","author":"Garay","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.phrs.2021.105761_bib255","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1600-0773.1993.tb01351.x","article-title":"Potential antidepressive properties of amantadine, memantine and bifemelane","volume":"72","author":"Moryl","year":"1993","journal-title":"Pharmacol. Toxicol."},{"key":"10.1016\/j.phrs.2021.105761_bib256","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.pbb.2004.01.006","article-title":"Antidepressant- and anxiolytic-like activity of magnesium in mice","volume":"78","author":"Poleszak","year":"2004","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.phrs.2021.105761_bib257","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1017\/neu.2015.14","article-title":"Effect of NMDAR antagonists in the tetrabenazine test for antidepressants: comparison with the tail suspension test","volume":"27","author":"Skolnick","year":"2015","journal-title":"Acta Neuropsychiatr."},{"key":"10.1016\/j.phrs.2021.105761_bib258","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/npp.2016.224","article-title":"Adjunctive Lanicemine (AZD6765) in patients with major mepressive misorder and history of inadequate response to antidepressants: a randomized, placebo-controlled study","volume":"42","author":"Sanacora","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.phrs.2021.105761_bib259","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/ALN.0b013e3181870a17","article-title":"Biologic effects of nitrous oxide: a mechanistic and toxicologic review","volume":"109","author":"Sanders","year":"2008","journal-title":"Anesthesiology"},{"key":"10.1016\/j.phrs.2021.105761_bib260","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40138-016-0092-3","article-title":"Nitrous oxide, from the operating room to the emergency department","volume":"4","author":"Huang","year":"2016","journal-title":"Curr. Emerg. Hosp. Med. Rep."},{"key":"10.1016\/j.phrs.2021.105761_bib261","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1213\/ANE.0b013e3182a7f73c","article-title":"Nitrous oxide for the management of labor pain: a systematic review","volume":"118","author":"Likis","year":"2014","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.phrs.2021.105761_bib262","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrn2153","article-title":"NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders","volume":"8","author":"Lau","year":"2007","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.phrs.2021.105761_bib263","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S0959-4388(03)00073-4","article-title":"Opposing roles of synaptic and extrasynaptic NMDA receptors in neuronal calcium signalling and BDNF gene regulation","volume":"13","author":"Vanhoutte","year":"2003","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.phrs.2021.105761_bib264","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1038\/npp.2014.123","article-title":"The role of GluN2A and GluN2B subunits on the effects of NMDA receptor antagonists in modeling schizophrenia and treating refractory depression","volume":"39","author":"Jim\u00e9nez-S\u00e1nchez","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.phrs.2021.105761_bib265","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.neuropharm.2017.08.006","article-title":"Involvement of extracellular signal-regulated kinase (ERK) in the short and long-lasting antidepressant-like activity of NMDA receptor antagonists (zinc and Ro 25-6981) in the forced swim test in rats","volume":"125","author":"Pochwat","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2021.105761_bib266","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.biopsych.2007.05.028","article-title":"Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors","volume":"63","author":"Maeng","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib267","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2174\/1568007024606258","article-title":"N-methyl-D-aspartate receptor-coupled glycineB receptors in the pathogenesis and treatment of schizophrenia: a critical review","volume":"1","author":"Millan","year":"2002","journal-title":"Curr. Drug Targets CNS Neurol. Disord."},{"key":"10.1016\/j.phrs.2021.105761_bib268","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0022-3565(24)37463-4","article-title":"Glycine site antagonists and partial agonists inhibit N-methyl-D-aspartate receptor-mediated [3H]arachidonic acid release in cerebellar granule cells","volume":"285","author":"Viu","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2021.105761_bib269","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jad.2006.03.004","article-title":"Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder","volume":"93","author":"Heresco-Levy","year":"2006","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.phrs.2021.105761_bib270","doi-asserted-by":"crossref","first-page":"737","DOI":"10.4088\/JCP.14l09527","article-title":"Single-dose ketamine followed by daily D-cycloserine in treatment-resistant bipolar depression","volume":"76","author":"Kantrowitz","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib271","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/ijnp\/pyy101","article-title":"Positive N-methyl-D-aspartate receptor modulation by rapastinel promotes rapid and sustained antidepressant-like effects","volume":"22","author":"Donello","year":"2019","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.phrs.2021.105761_bib272","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/13543784.2019.1559295","article-title":"Rapastinel \u2013 an investigational NMDA-R modulator for major depressive disorder: evidence to date","volume":"28","author":"Ragguett","year":"2019","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.phrs.2021.105761_bib273","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/01.pra.0000462606.17725.93","article-title":"Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent","volume":"21","author":"Preskorn","year":"2015","journal-title":"J. Psychiatr. Pract."},{"key":"10.1016\/j.phrs.2021.105761_bib274","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.bbr.2015.10.060","article-title":"GLYX-13 (rapastinel) ameliorates subchronic phencyclidine- and ketamine-induced declarative memory deficits in mice","volume":"299","author":"Rajagopal","year":"2016","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.phrs.2021.105761_bib275","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1017\/S1092852919001159","article-title":"Keeping up with the clinical advances: depression","volume":"24","author":"Ragguett","year":"2019","journal-title":"CNS Spectr."},{"key":"10.1016\/j.phrs.2021.105761_bib276","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2019.172827","article-title":"Rapastinel, a novel glutamatergic agent with ketamine-like antidepressant actions: convergent mechanisms","volume":"188","author":"Kato","year":"2020","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.phrs.2021.105761_bib277","unstructured":"Allergan, Allergan Announces Phase 3 Results for Rapastinel as an Adjunctive Treatment of Major Depressive Disorder (MDD), 2019. \u3008https:\/\/www.prnewswire.com\/news-releases\/allergan-announces-phase-3-results-for-rapastinel-as-an-adjunctive-treatment-of-major-depressive-disorder-mdd-300808044.html\u3009."},{"key":"10.1016\/j.phrs.2021.105761_bib278","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1046\/j.1460-9568.2003.02657.x","article-title":"Expression and functional role of mGluR3 and mGluR5 in human astrocytes and glioma cells: opposite regulation of glutamate transporter proteins","volume":"17","author":"Aronica","year":"2003","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.phrs.2021.105761_bib279","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1523\/JNEUROSCI.17-19-07503.1997","article-title":"Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus","volume":"17","author":"Shigemoto","year":"1997","journal-title":"J. Neurosci."},{"key":"10.1016\/j.phrs.2021.105761_bib280","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1124\/jpet.116.233627","article-title":"The rapidly acting antidepressant ketamine and the mGlu2\/3 receptor antagonist LY341495 rapidly engage dopaminergic mood circuits","volume":"358","author":"Witkin","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2021.105761_bib281","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.neuropharm.2012.04.007","article-title":"Negative allosteric modulation of metabotropic glutamate receptor 5 results in broad spectrum activity relevant to treatment resistant depression","volume":"66","author":"Hughes","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2021.105761_bib282","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/2049-9256-1-15","article-title":"mGluR2\/3 blockade produces rapid and long-lasting reversal of anhedonia caused by chronic stress exposure","volume":"1","author":"Dwyer","year":"2013","journal-title":"J. Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib283","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.pnpbp.2016.01.009","article-title":"Efficacy and safety of an adjunctive mGlu2 receptor positive allosteric modulator to a SSRI\/SNRI in anxious depression","volume":"67","author":"Kent","year":"2016","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2021.105761_bib284","unstructured":"First-in-Human Study With Single and Multiple Doses of TS-161 in Healthy Participants. \u3008https:\/\/ClinicalTrials.gov\/show\/NCT03919409\u3009."},{"key":"10.1016\/j.phrs.2021.105761_bib285","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/hup.2475","article-title":"The use of ketamine as an antidepressant: a systematic review and meta-analysis","volume":"30","author":"Coyle","year":"2015","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.phrs.2021.105761_bib286","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2215-0366(17)30272-9","article-title":"Side-effects associated with ketamine use in depression: a systematic review","volume":"5","author":"Short","year":"2018","journal-title":"Lancet Psychiatry"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821003455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821003455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:24:33Z","timestamp":1760912673000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661821003455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":286,"alternative-id":["S1043661821003455"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105761","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel rapid-acting glutamatergic modulators: Targeting the synaptic plasticity in depression","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105761","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105761"}}